Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo (FFX/bev) in the first-line treatment ...
Today a whole body exam could involve up to 76 receiver chains and the current industry trend is to increase the channel count even further. The higher integration of high-performance analog functions ...
Prognostic value of circulating tumor DNA for progression-free survival in patients with locally advanced dMMR/MSI-H colorectal cancer managed without surgery. Genomic alterations in circulating tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results